Dimension Therapeutics Inc. (NASDAQ:DMTX)’s share price traded up 5.5% during trading on Monday . The company traded as high as $9.98 and last traded at $9.81, with a volume of 173,280 shares. The stock had previously closed at $9.30.

DMTX has been the subject of several research reports. Chardan Capital set a $10.00 price objective on shares of Dimension Therapeutics and gave the company a “hold” rating in a research report on Sunday, August 21st. Zacks Investment Research cut shares of Dimension Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Cantor Fitzgerald initiated coverage on shares of Dimension Therapeutics in a research report on Thursday, June 2nd. They issued a “buy” rating and a $32.00 price objective for the company. Jefferies Group set a $12.00 price objective on shares of Dimension Therapeutics and gave the company a “buy” rating in a research report on Monday, September 12th. Finally, Canaccord Genuity set a $20.00 price objective on shares of Dimension Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 11th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $17.19.

The firm’s market capitalization is $237.27 million. The firm has a 50 day moving average of $7.14 and a 200 day moving average of $7.45.

Dimension Therapeutics (NASDAQ:DMTX) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Dimension Therapeutics had a negative return on equity of 66.58% and a negative net margin of 459.47%. Equities analysts expect that Dimension Therapeutics Inc. will post ($1.91) earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the company. Teachers Advisors Inc. boosted its stake in Dimension Therapeutics by 224.3% in the second quarter. Teachers Advisors Inc. now owns 19,204 shares of the company’s stock valued at $115,000 after buying an additional 13,283 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in Dimension Therapeutics during the second quarter valued at about $123,000. Bridgeway Capital Management Inc. purchased a new stake in Dimension Therapeutics during the second quarter valued at about $128,000. A.R.T. Advisors LLC purchased a new stake in Dimension Therapeutics during the second quarter valued at about $134,000. Finally, California State Teachers Retirement System boosted its stake in Dimension Therapeutics by 113.2% in the second quarter. California State Teachers Retirement System now owns 25,634 shares of the company’s stock valued at $154,000 after buying an additional 13,610 shares during the last quarter. Hedge funds and other institutional investors own 85.80% of the company’s stock.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.